<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226550</url>
  </required_header>
  <id_info>
    <org_study_id>2004.368</org_study_id>
    <nct_id>NCT01226550</nct_id>
  </id_info>
  <brief_title>Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan</brief_title>
  <official_title>Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, non-randomized, phase I-II, pilot study, which evaluates the combination of
      optimum cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy (HIPEC)
      with mitomycin C (MMC) and irinotecan. The latter drug will be administered in escalating
      doses to patients with gastric, colorectal, appendicular, or primary peritoneal carcinosis
      (PC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity rate</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>postoperative complications (class III and IV, Common Terminology Criteria V3; National Cancer Institute)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>30 days postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraperitoneal and serumal concentration (pharmacokinetics) of mitomycine C, irinotecan, and its metabolites.</measure>
    <time_frame>per-HIPEC</time_frame>
    <description>Plasma, peritoneal, and urinary values for MMC, irinotecan, SN-38, SN-38G, APC, and NPC.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Peritoneal Carcinosis (PC)</condition>
  <arm_group>
    <arm_group_label>cytoreductive surgery and HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cytoreductive surgery and HIPEC</intervention_name>
    <description>The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).
The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.
Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU).</description>
    <arm_group_label>cytoreductive surgery and HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a peritoneal carcinosis (PC) either of digestive origin or primary: a
             colorectal or gastric carcinosis, a peritoneal pseudomyxoma or mesothelioma, or a
             primary carcinosis of the peritoneum regardless the number of prior treatment lines.

          -  A PC and primary tumor considered to be resectable according to preoperative clinical
             and paraclinical data: absence of mesenteric retraction and absence of bladder
             invasion.

          -  Patients in good general health (ASA ≤ 2).

          -  Absence of cardiorespiratory failure (PaO2 &gt; 60 mmHg in a stable condition, dyspnea ≤
             NYHA stage 1, left ventricular ejection fraction &gt; 60%.).

          -  Prothrombin level &gt;70 %, total bilirubin &lt; 2 x the normal level, ASAT and ALAT &lt; 2.5 x
             normal levels, and alkaline phosphatases &lt; 5 x normal levels.

          -  Creatinine clearance &gt; 60 ml/min, polynuclear neutrophils &gt; 1500/mm3, and a white
             blood cell count &gt; 4000 /mm3.

          -  Patients who give written, informed consent.

          -  Patients affiliated with the French universal healthcare system.

        Exclusion Criteria:

          -  Patients with a PC with ovarian, mammary, biliary, pancreatic, or bronchial origin.

          -  Evolutive patients after systemic chemotherapy.

          -  Patients with a PC considered to be irresectable according to preoperative clinical
             and paraclinical data: mesenteric retraction or bladder invasion.

          -  Patients in poor general health (ASA &gt; 2).

          -  Cardiorespiratory failure (dyspnea &gt; NYHA stage 1, PaO2 &lt; 60 mmHg in a stable
             condition)

          -  Prothrombin level &lt; 70 %.

          -  Any brain abnormality showing on the head scan.

          -  Signs of heart failure and especially left ventricular ejection fraction &lt; 60% on the
             cardiac ultrasound.

          -  Thrombocytopenia &lt; 100 000 / mm3

          -  Visceral metastases other than a single resectable liver metastasis.

          -  Pregnancy or breast feeding.

          -  Chronic inflammatory intestinal disease and/or an intestinal obstruction.

          -  History of severe hypersensitivity to irinotecan hydrochloride trihydrate or one of
             the excipients of Campto.

          -  Bilirubinemia &gt; 3 times the normal upper limit

          -  Yellow fever vaccine.

          -  Prophylactic treatment with phenytoin.

          -  Severe medullary insufficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de Chirurgie Générale et Thoracique, Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>December 28, 2011</last_update_submitted>
  <last_update_submitted_qc>December 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperthermic intraoperative peritoneal chemotherapy (HIPEC)</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>peritoneal carcinomatosis (PC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

